Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07539090
PHASE1

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Sponsor: Deciphera Pharmaceuticals, LLC

View on ClinicalTrials.gov

Summary

The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.

Official title: A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) in Healthy Female Participants

Key Details

Gender

FEMALE

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2026-06

Completion Date

2026-08

Last Updated

2026-06-05

Healthy Volunteers

Yes

Interventions

DRUG

Vimseltinib

Administered orally

DRUG

Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])

Administered orally

Locations (1)

Nucleus Network

Saint Paul, Minnesota, United States